erlotinib hydrochloride has been researched along with HPV Infection in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aderhold, C; Birk, R; Huber, L; Kramer, B; Mueller, CE; Rotter, N; Schell, A | 1 |
| Castillo, P; González-Sánchez, N; Grau, JJ; Haag, O; Remacha, J; Rojas-Lechuga, MJ; Vilaseca, I | 1 |
| Hsu, JH; Li, MF; Shiau, EL; Wu, MT | 1 |
| Biddinger, P; Dillard, T; Hao, Z; Patel, V | 1 |
| Diefendorf, LP; Jette, DF; Mohammed, A; Mondal, S; Moses, MA; Searleman, SA; Stevens, DA; Wilton, KM; Woodworth, CD | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
6 other study(ies) available for erlotinib hydrochloride and HPV Infection
| Article | Year |
|---|---|
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Papillomavirus Infections; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Squamous Cell Carcinoma of Head and Neck | 2020 |
Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report.
Topics: Adolescent; Antineoplastic Agents; Celecoxib; Child; Child, Preschool; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Erlotinib Hydrochloride; Female; Humans; Papillomavirus Infections; Respiratory Tract Infections; Retreatment; Young Adult | 2020 |
Recurrent respiratory papillomatosis with lung involvement and malignant transformation.
Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.
Topics: Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Erlotinib Hydrochloride; Humans; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Thoracic Surgery, Video-Assisted | 2013 |
Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.
Topics: Apoptosis; Cell Transformation, Viral; Cervix Uteri; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Viral; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Repressor Proteins; Signal Transduction; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |